Superiority of escitalopram to paroxetine in the treatment of depression
Superiority of escitalopram to paroxetine in the treatment of depression
Post-hoc pooled analysis of data from two 6-month randomised controlled trials in patients with major depressive disorder (MDD) revealed superior efficacy and tolerability of escitalopram when compared with paroxetine. Escitalopram (n = 394) produced a significantly (p < 0.01) greater mean treatment difference of 2.0 points in primary endpoints, judged using the Montgomery–Åsberg Depression Rating Scale (MADRS) total score, compared with paroxetine (n = 383). Significant differences were also observed in Clinical Global Impression (CGI) — severity (escitalopram, 2.1; paroxetine, 2.4; p < 0.01) and CGI — improvement (escitalopram, 1.8; paroxetine, 2.0: p < 0.01). In the sub-group of severely depressed patients (baseline MADRS ? 30), escitalopram showed further improved efficacy compared with paroxetine in all scores. This analysis supports previous observations of superior efficacy and tolerability of long-term escitalopram treatment (10 to 20 mg/day) compared with paroxetine (20 to 40 mg/day). Escitalopram is a good therapeutic option for the long-term treatment of MDD, particularly in severely depressed patients.
escitalopram, major depressive disorder (MDD), selective serotonin reuptake inhibitors (SSRIs), severe depression, paroxetine
229-237
Kasper, Siegfried
b9a183a1-5cae-422c-b143-482a8f06cb83
Baldwin, David S.
1beaa192-0ef1-4914-897a-3a49fc2ed15e
Lönn, Sara Larsson
f7c8fc42-3aa8-4417-b1a4-7b7921d51278
Boulenger, Jean-Philippe
2ffca63f-42c6-499d-bd42-404cd460654e
April 2009
Kasper, Siegfried
b9a183a1-5cae-422c-b143-482a8f06cb83
Baldwin, David S.
1beaa192-0ef1-4914-897a-3a49fc2ed15e
Lönn, Sara Larsson
f7c8fc42-3aa8-4417-b1a4-7b7921d51278
Boulenger, Jean-Philippe
2ffca63f-42c6-499d-bd42-404cd460654e
Kasper, Siegfried, Baldwin, David S., Lönn, Sara Larsson and Boulenger, Jean-Philippe
(2009)
Superiority of escitalopram to paroxetine in the treatment of depression.
European Neuropsychopharmacology, 19 (4), .
(doi:10.1016/j.euroneuro.2008.12.003).
Abstract
Post-hoc pooled analysis of data from two 6-month randomised controlled trials in patients with major depressive disorder (MDD) revealed superior efficacy and tolerability of escitalopram when compared with paroxetine. Escitalopram (n = 394) produced a significantly (p < 0.01) greater mean treatment difference of 2.0 points in primary endpoints, judged using the Montgomery–Åsberg Depression Rating Scale (MADRS) total score, compared with paroxetine (n = 383). Significant differences were also observed in Clinical Global Impression (CGI) — severity (escitalopram, 2.1; paroxetine, 2.4; p < 0.01) and CGI — improvement (escitalopram, 1.8; paroxetine, 2.0: p < 0.01). In the sub-group of severely depressed patients (baseline MADRS ? 30), escitalopram showed further improved efficacy compared with paroxetine in all scores. This analysis supports previous observations of superior efficacy and tolerability of long-term escitalopram treatment (10 to 20 mg/day) compared with paroxetine (20 to 40 mg/day). Escitalopram is a good therapeutic option for the long-term treatment of MDD, particularly in severely depressed patients.
This record has no associated files available for download.
More information
Published date: April 2009
Keywords:
escitalopram, major depressive disorder (MDD), selective serotonin reuptake inhibitors (SSRIs), severe depression, paroxetine
Identifiers
Local EPrints ID: 148035
URI: http://eprints.soton.ac.uk/id/eprint/148035
ISSN: 0924-977X
PURE UUID: 063f4694-e40e-4fc8-ab6a-e309f40ad512
Catalogue record
Date deposited: 27 Apr 2010 09:39
Last modified: 14 Mar 2024 02:38
Export record
Altmetrics
Contributors
Author:
Siegfried Kasper
Author:
Sara Larsson Lönn
Author:
Jean-Philippe Boulenger
Download statistics
Downloads from ePrints over the past year. Other digital versions may also be available to download e.g. from the publisher's website.
View more statistics